Announcements Trials

Browse Landscape

Status

Unknown 1 Completed 1

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 4 Melanoma 2 Uterine Cervical Neoplasms 1 Solid Tumor, Adult 1 Skin Neoplasms 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Neuromyelitis Optica 1 Neoplasms, Second Primary 1 Neoplasm Metastasis 1 Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease 1 Myasthenia Gravis 1 Multiple Sclerosis 1 Lung Neoplasms 1 Laryngectomy; Status 1 Hematologic Neoplasms 1 Hematologic Diseases 1 Endometrial Neoplasms 1 Encephalomyelitis, Acute Disseminated 1 Carcinoma, Renal Cell 1 COVID-19 1 Autoimmune Diseases of the Nervous System 1

Interventions

Sunitinib 14 aldesleukin 10 Bevacizumab 8 pembrolizumab 7 Nivolumab 7 pazopanib 5 Axitinib 5 atezolizumab 4 Interferon-alpha 4 sintilimab 3 durvalumab 3 Sorafenib 3 Everolimus 3 Cyclophosphamide 3 Chemotherapy, Adjuvant 3 toripalimab 2 sargramostim 2 olaparib 2 lenvatinib 2 fludarabine phosphate 2 camrelizumab 2 avelumab 2 Neoadjuvant Therapy 2 Laparoscopy 2 Ipilimumab 2 Interferon alpha-2 2 Immunohistochemistry 2 Immune Checkpoint Inhibitors 2 Gene Expression Profiling 2 Fluorouracil 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Carcinoma, Renal Cell × Data Collection × Clear all

NCT05456074 2022-11-25

IMCOR

Institut de cancérologie Strasbourg Europe

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡